Royalty Pharma PLC (RPRX) has declared a quarterly dividend of $0.22 per share, payable to shareholders of record. The ex-dividend date is set for November 13, 2025, meaning investors must own shares prior to this date to qualify for the payment. The dividend will be disbursed on December 9, 2025.
With a dividend yield of 2.28%, Royalty Pharma continues its commitment to providing regular income to shareholders. This yield represents the annual dividend income relative to the stock price. The company's ongoing pattern of dividend payments reflects its cash flow generation and capital allocation strategy.
Royalty Pharma, headquartered in New York City, engages in drug development services and collaborates with both small and mid-cap biotechnology firms and global pharmaceutical companies. The firm has a market capitalization of $22.5 billion and a P/E ratio of 22.09, with an EPS of 1.74. It maintains a diverse portfolio that includes royalties on more than 35 commercial products, such as Vertex’s Trikafta and GSK’s Trelegy.
The upcoming earnings report is scheduled for August 3, 2026, with an expected EPS of $1.44 and revenue of $774.2 million. Such decisions reflect the company’s focus on sustaining its dividend amidst its financial performance and overall market conditions.